Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy

Molecular Therapy

Volumn 2, Issue 3, 2000, Pages 195-203

  Lohr, Frank ^a   Hu, Kang ^a   Haroon, Zishan ^a   Samulski, Thaddeus V ^a   Huang, Qian ^a   Beaty, Jennifer ^a   Dewhirst, Mark W ^a   Li, Chuan Yuan ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Costimulatory molecules; IL12; Immunotherapy; Interleukin 12; Multi modality therapy; Radiotherapy

Indexed keywords

ADENOVIRIDAE; MURINAE;

B7 ANTIGEN; INTERLEUKIN 12;

ADENOVIRUS; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; C57BL MOUSE; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL NEOPLASM; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; NATURAL KILLER CELL; RADIATION DOSE FRACTIONATION;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD80; DOSE FRACTIONATION; GENE EXPRESSION; IMMUNOTHERAPY; INTERLEUKIN-12; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034267894     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0114     Document Type: Article

References (41)

1. Sigel, J., and Puri, R. (1991). Interleukin-2 toxicity. J. Clin. Oncol. 9: 694-704.
2. Spriggs, D., and Yates, S. (1992). Secondary cancer chemotherapy: Experiences with TNF administration in humans. In Tumor Necrosis Factor, the Molecules and Their Emerging Roles in Medicine (B. Beutler, Ed.), pp. 383-406. Raven Press, New York.
3. Ryffel, B. (1997). Interleukin-12: Role of interferon-gamma in IL-12 adverse effects [see comments], Clin. Immunol. Immunopathol. 83: 18-20.
4. Lotze, M. T., et al. (1997). The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy. Cancer J. Sci. Am. 3: S109-S114.
5. Rakhmilevich, A. L., Janssen, K., Turner, J., Gulp, J., and Yang, N. S. (1997). Cytokine gene therapy of cancer using gene gun technology: Superior antitumor activity of interleukin-12. Hum. Gene Ther. 8: 1303-1311.
6. Carroll, M. W., Overwijk, W. W., Surman, D. R., Tsung, K., Moss, B., and Restifo, N. P. (1998). Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen. J. Natl. Cancer Inst. 90: 1881-1887.
7. Coughlin, C. M., Wysocka, M., Kurzawa, H. L., Lee, W. M., Trinchieri, G., and Eck, S. L. (1995). B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res. 55: 4980-4987.
8. Townsend, S. E., and Allison, J. P. (1993). Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells [see comments]. Science 259: 368-370.
9. Chong, H., Todryk, S., Hutchinson, G., Hart, I. R., and Vile, R. G. (1998). Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity. Gene Ther. 5: 223-232.
10. Hurwitz, A. A., Townsend, S. E., Yu, T. F., Wallin, J. A., and Allison, J. P. (1998). Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma. Int. J. Cancer 77: 107-113.
11. Puetzer, B. M., Hitt, M., Muller, W. J., Emtage, P., Gauldie, J., and Graham, F. L. (1997). Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc. Natl. Acad. Sci. USA 94: 10889-10894.
12. Puisieux, I., et al. (1998). Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity [see comments]. Hum. Gene Ther. 9: 2481-2492.
13. Golab, J., and Zagozdzon, R. (1999). Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (Review). Int. J. Mol. Med. 3: 537-544.
14. Aslakson, C. J., and Millier, F. R. (1992). Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52: 1399-1405.
15. Graham, F. L., and Prevec, L. (1995). Methods for construction of adenovirus vectors. Mol. Biotechnol. 3: 207-220.
16. Hsu, S. M., Raine, L., and Fanger, H. (1981). Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 29: 577-580.
17. Holm, G., and Perlmann, P. (1967). Quantitative studies on phytohaemagglutinin-induced cytotoxicity by human lymphocytes against homologous cells in tissue culture. Immunology 12: 525-536.
18. Barth, R. J., Jr., Bock, S. N., Mule, J. J., and Rosenberg, S. A. (1990). Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. J. Immunol. 144: 1531-1537.
19. Nagasawa, H., and Little, J. B. (1988). Radiosensitivities of ten apparently normal human diploid fibroblast strains to cell killing, G2-phase chromosomal aberrations, and cell cycle delay. Cancer Res. 48: 4535-4538.
20. Nasu, Y., et al. (1999). Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther. 6: 338-349.
21. Foster, B., Gingrich, J., Kwon, E., Madias, C., and Greenberg, N. (1997). Characterization of prostate epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 57: 3325-3330.
22. Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J., and Folkman, J. (1995). Inhibition of angiogenesis in vivo by interleukin 12 [see comments]. J. Natl. Cancer Inst. 87: 581-586.
23. Coughlin, C. M., et al. (1998). Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 101: 1441-1452.
24. Guffey, J. M., et al. (1995). Immunohistochemical assessment of tumor vascularity in recurrent Clark II melanomas using antibody to type IV collagen. J. Cutan. Pathol. 22: 122-127.
25. Bonnekoh, B., et al. (1998). Adenovirus-mediated ex vivo immunogene and in vivo combination gene therapy strategies induce a systemic anti-tumor immune defense in the mouse B16 melanoma model. Adv. Exp. Med. Biol. 451: 335-343.
26. Cole, S., Lewkowicz, S. J., and Townsend, K. M. (1984). Langerhans cell number and morphology in mouse footpad epidermis after X irradiation. Radiat. Res. 100: 594-606.
27. Oboshi, S., Shimosato, Y., Itakura, K., and Umegaky, S. (1967). Radiation pathology for cancer II: The immunological significance of the infiltration of lymphocytes surrounding the tumor tissue during irradiation. Igakunoyumi 61: 725-730.
28. Yamashita, T., Mizukoshi, T., Tomita, K., and Kobayashi, H. (1987). Anti-tumor immunity and tumor metastases as influenced by the radiation dosage in local radiotherapy. Can No Rinsho 33: 1205-1210.
29. Teicher, B. A., Ara, G., Buxton, D., Leonard, J., and Schaub, R. G. (1998). Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine Lewis lung carcinoma. Radiat. Oncol. Invest. 6: 71-80.
30. Seetharam, S., et al. (1999). Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation. Int. J. Oncol. 15: 769-773.
31. Yang, T. C., et al. (1980). Enhancement effects of high-energy neon particles on the viral transformation of mouse C3H1OT1/2 cells in vitro. Radiat. Res. 81: 208-223.
32. Su, Z. Z., Zhang, P. Q., Geard, C., and Fisher, P. B. (1990). Enhancement of adenovirus transformation of cloned rat embryo fibroblast cells by gamma irradiation. Mol. Carcinog. 3: 141-149.
33. Zeng, M., Cerniglia, G. J., Eck, S. L., and Stevens, C. W. (1997). High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation. Hum. Gene Ther. 8: 1025-1032.
34. Santin, A., et al. (1997). Effects of irradiation on the expression of major histocompatibility complex class I antigen and adhesion costimulation molecules icam-1 in human cervical cancer. IJROBP 29: 737-742.
35. Santin, A., et al. (1998). The effects of irradiation on the expression of a tumor rejection antigen (heat shock protein gp96) in human cervical cancer. Int. J. Radiat. Biol. 73: 699-704.
36. Albert, M. L., Sauter, B., and Bhardwaj, N. (1998). Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392: 86-89.
37. Brunda, M. J., et al. (1993). Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178: 1223-1230.
38. Fernandez, N. C., Levraud, J. P., Haddada, H., Perricaudet, M., and Kourilsky, P. (1999). High frequency of specific CD8+ T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer. J. Immunol. 162: 609-617.
39. Dighe, A. S., Richards, E., Old, L. J., and Schreiber, R. D. (1994). Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1: 447-456.
40. Kurzawa, H., Wysocka, M., Aruga, E., Chang, A. E., Trinchieri, G., and Lee, W. M. (1998). Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression. Cancer Res. 58: 491-499.
41. Bramson, J. L., Hitt, M., Gauldie, J., and Graham, F. L. (1997). Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther. 4: 1069-1076.